Pembrolizumab provides long‐term survival benefits in advanced non‐small cell lung cancer: The 5‐year outcomes of the KEYNOTE‐024 trial
Guardado en:
| Autores principales: | , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Wiley
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/a69bfb0defa04ea3b11f96a5ccff03e2 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:a69bfb0defa04ea3b11f96a5ccff03e2 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:a69bfb0defa04ea3b11f96a5ccff03e22021-12-02T02:34:55ZPembrolizumab provides long‐term survival benefits in advanced non‐small cell lung cancer: The 5‐year outcomes of the KEYNOTE‐024 trial1759-77141759-770610.1111/1759-7714.14193https://doaj.org/article/a69bfb0defa04ea3b11f96a5ccff03e22021-12-01T00:00:00Zhttps://doi.org/10.1111/1759-7714.14193https://doaj.org/toc/1759-7706https://doaj.org/toc/1759-7714Fengtan LiXifeng DongWileyarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENThoracic Cancer, Vol 12, Iss 23, Pp 3085-3087 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 |
| spellingShingle |
Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Fengtan Li Xifeng Dong Pembrolizumab provides long‐term survival benefits in advanced non‐small cell lung cancer: The 5‐year outcomes of the KEYNOTE‐024 trial |
| format |
article |
| author |
Fengtan Li Xifeng Dong |
| author_facet |
Fengtan Li Xifeng Dong |
| author_sort |
Fengtan Li |
| title |
Pembrolizumab provides long‐term survival benefits in advanced non‐small cell lung cancer: The 5‐year outcomes of the KEYNOTE‐024 trial |
| title_short |
Pembrolizumab provides long‐term survival benefits in advanced non‐small cell lung cancer: The 5‐year outcomes of the KEYNOTE‐024 trial |
| title_full |
Pembrolizumab provides long‐term survival benefits in advanced non‐small cell lung cancer: The 5‐year outcomes of the KEYNOTE‐024 trial |
| title_fullStr |
Pembrolizumab provides long‐term survival benefits in advanced non‐small cell lung cancer: The 5‐year outcomes of the KEYNOTE‐024 trial |
| title_full_unstemmed |
Pembrolizumab provides long‐term survival benefits in advanced non‐small cell lung cancer: The 5‐year outcomes of the KEYNOTE‐024 trial |
| title_sort |
pembrolizumab provides long‐term survival benefits in advanced non‐small cell lung cancer: the 5‐year outcomes of the keynote‐024 trial |
| publisher |
Wiley |
| publishDate |
2021 |
| url |
https://doaj.org/article/a69bfb0defa04ea3b11f96a5ccff03e2 |
| work_keys_str_mv |
AT fengtanli pembrolizumabprovideslongtermsurvivalbenefitsinadvancednonsmallcelllungcancerthe5yearoutcomesofthekeynote024trial AT xifengdong pembrolizumabprovideslongtermsurvivalbenefitsinadvancednonsmallcelllungcancerthe5yearoutcomesofthekeynote024trial |
| _version_ |
1718402368257654784 |